In 2023, the Food and Drug Administration approved the first two RSV vaccines for adults aged ≥60 years ( 4), making the 2023–2024 respiratory virus season the first in which vaccines against SARS-CoV-2, influenza, and RSV are simultaneously available in the United States. Nursing home residents are at risk for becoming infected with and experiencing severe complications from respiratory viruses, including SARS-CoV-2 ( 1), influenza ( 2), and respiratory syncytial virus (RSV) ( 3).

There is an urgent need to protect nursing home residents against severe outcomes of respiratory illnesses by continuing efforts to increase vaccination against COVID-19 and influenza and discussing vaccination against RSV with eligible residents during the ongoing 2023–24 respiratory virus season. Department of Health and Human Services region, social vulnerability index level, and facility size. Among residents at 20.2% and 19.4% of facilities that elected to report, coverage with influenza and RSV vaccines was 72.0% and 9.8%, respectively. As of December 10, 2023, 33.1% of nursing home residents were up to date with vaccination against COVID-19. The purpose of this study was to assess COVID-19, influenza, and RSV vaccination coverage among nursing home residents during the current 2023–24 respiratory virus season. Nursing homes are required to report COVID-19 vaccination coverage and can voluntarily report influenza and RSV vaccination coverage among residents to CDC’s National Healthcare Safety Network. Fall 2023 is the first season during which vaccines are simultaneously available to protect older adults in the United States against all three of these respiratory viruses.

Nursing home residents are at risk for becoming infected with and experiencing severe complications from respiratory viruses, including SARS-CoV-2, influenza, and respiratory syncytial virus (RSV).

Instal the new NoScript 11.4.27